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Abstract
APE1/Ref-1 is a main regulator of cellular response to oxidative stress via DNA-repair function and co-activating activity on
the NF-kB transcription factor. APE1 is central in controlling the oxidative stress-based inflammatory processes through
modulation of cytokines expression and its overexpression is responsible for the onset of chemoresistance in different
tumors including hepatic cancer. We examined the functional role of APE1 overexpression during hepatic cell damage
related to fatty acid accumulation and the role of the redox function of APE1 in the inflammatory process. HepG2 cells were
stably transfected with functional and non-functional APE1 encoding plasmids and the protective effect of APE1
overexpression toward genotoxic compounds or FAs accumulation, was tested. JHH6 cells were stimulated with TNF-a in
the presence or absence of E3330, an APE1 redox inhibitor. IL-8 promoter activity was assessed by a luciferase reporter
assay, gene expression by Real-Time PCR and cytokines (IL-6, IL-8, IL-12) levels measured by ELISA. APE1 over-expression did
not prevent cytotoxicity induced by lipid accumulation. E3330 treatment prevented the functional activation of NF-kB via
the alteration of APE1 subcellular trafficking and reduced IL-6 and IL-8 expression induced by TNF-a and FAs accumulation
through blockage of the redox-mediated activation of NF-kB. APE1 overexpression observed in hepatic cancer cells may
reflect an adaptive response to cell damage and may be responsible for further cell resistance to chemotherapy and for the
onset of inflammatory response. The efficacy of the inhibition of APE1 redox activity in blocking TNF-a and FAs induced
inflammatory response opens new perspectives for treatment of inflammatory-based liver diseases.
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Introduction
Non-alcoholic steatohepatitis (NASH) defines a distinct hepatic
disorder observed in patients without a history of alcohol abuse
that histologically resembles alcohol-induced liver damage and
includes cellular damage, inflammation and fibrosis [1] and may
evolve towards cirrhosis, liver failure and HCC [2]. The
mechanisms of this progression and the pathogenesis of NASH
are still poorly understood although oxidative stress, generated as a
consequence of mitochondrial impairment, seems to be directly
linked with the onset of the inflammatory circuits responsible for
the progression of this pathology. One of the key pro-inflamma-
tory cytokines that appears to be involved in modulating the
inflammatory response in several forms of liver injury is
interleukin-8 (IL-8) [3], a CXC chemokine, that recruits and
activates neutrophils, basophils and T cells [4]. Since patients with
NASH have significantly elevated serum levels of IL-8 compared
with healthy individuals, IL-8 may play a key role in the
pathogenesis of NASH [5]. In different hepatic in vitro models,
lipid accumulation can stimulate IL-8 production [6] through
activation of NF-kB [7]. In the rat liver, free Fatty Acids (FAs)
activate the NF-kB pathway and increase the expression of some
pro-inflammatory cytokines (TNF-a, IL-1b, IL-6) [8,9].
The Apurinic apyrimidinic Endonuclease/Redox effector factor
1 (APE1/Ref-1) is a multifunction protein that acts as a master
regulator of cellular response to oxidative stress conditions and
contributes to the maintenance of genome stability. APE1 is
involved in both the base excision repair (BER) pathways of DNA
lesions, acting as the major apurinic/apyrimidinic (AP) endonu-
clease, and in transcriptional regulation of gene expression as a
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redox co-activator of different transcription factors, such NF-kB
and others [10,11]. In gastric epithelial cells APE1 plays a leading
role in controlling the onset of oxidative stress-based inflammatory
processes through modulating NF-kB-mediated IL-8 gene expres-
sion [12]. APE1 expression is also up-regulated during hepatic
lipid accumulation in NASH patients [13], although it is still
unknown whether this upregulation has a causal role in the onset
of NASH or is associated to a protective function on lipid
accumulation cytotoxic effect.
APE1 is upregulated in liver cancers [14], but the functional
role of this overexpression in tumor pathogenesis and progression
is not yet clear. APE1 redox function is exerted through a novel
redox-based mechanism involving three cysteine residues (i.e. C65,
C93 and C99) [15]. Recent in vitro studies demonstrated that APE1
adopts different unfolded conformations depending on the redox
state of its Cys residues [15]. The (E)-3-(2-[5,6-dimethoxy-3-
methyl-1,4-benzoquinonyl])-2-nonyl propenoic acid (E3330) has
been reported to directly bind APE1 protein and to inhibit its
redox activity, without interfering with its endonuclease activity,
by increasing the formation of disulfide bonds involving the redox-
active Cys65, altering the folding of APE1 protein and decreasing
the protein redox active population [16], thus impacting on APE1
subcellular trafficking [17]. E3330 holds clinical therapeutic
potential as a specific inhibitor of APE1 redox function [18].
The importance of this function is highlighted by results
demonstrating that NF-kB-mediated gene expression is regulated
by APE1 redox activity, without effects on IkBa degradation [19].
E3330 was also found to selectively inhibit growth/migration of
human pancreatic cancer cells [20], suggesting that the APE1
redox function could represent a good candidate for inhibition of
tumor invasion and metastasis. E3330 suppressed inflammatory
response in activated macrophages [21], suggesting the possible
use of E3330 to reduce the inflammatory processes in liver
diseases, such as those associated to NASH.
In this study, we used in vitro models of fat overloading obtained
by exposing hepatic cells to a mixture of long-chain FAs (palmitic
(C16:0) and oleic (C18:1) acids that are the most abundant FAs in
liver triglycerides [22,23]. Additionally, the present study was
aimed at examining the functional role of APE1 overexpression
during hepatic cell damage related to lipid accumulation and the
role of the redox function of APE1 in the inflammatory process
triggered by TNF-a and FAs accumulation. Our data demonstrate
that APE1 overexpression does not protect from FAs induced cell
damage and that APE1 and NF-kB play an essential role in TNF-
a-induced transcriptional activation of IL-8 gene expression in
hepatic cancer cell lines. Inhibition of APE1 redox activity by the
redox inhibitor E3330 is efficient in preventing both TNF-a or
lipid accumulation induced activation of IL-8 expression at the
transcriptional level through the blockage of the redox-mediated
activation of NF-kB.
Materials and Methods
Cell culture and treatments
In this study, we used the Huh-7 (differentiated hepatocyte
derived cellular carcinoma cell line) [24], the HepG2 (differenti-
ated hepatocellular carcinoma) [25] and the JHH6 (undifferenti-
ated hepatocellular carcinoma) [26] as models of the liver
tumorigenic process. Huh-7 and JHH6 were purchased from
Health Science Research Resources Bank (Osaka, Japan) while
HepG2 from ATCC. Huh-7 and HepG2 cells were cultured in
Dulbecco’s modified Eagle’s medium (EuroClone, Pero, IT),
JHH6 cells were cultured in William’s medium E (Sigma-Aldrich,
St Louis, MO), both supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Euroclone, Milan, IT).
HepG2 cell clones were cultured at a density of 70000 cells/cm2
and were treated with different doses of methyl methanesulfonate
(MMS) or 2.5 mM H2O2 (both reagents are distributed by Sigma-
Aldrich) for 2 h or 1 h respectively.
For etoposide treatment, HepG2 cell clones were trypsinized
and 400000 cells were seeded on glass coverslips in 6-wells culture
plates. After 24 h, medium was replaced by Dulbecco’s modified
Eagle’s medium (DMEM) with or without etoposide (Sigma, St
Louis, MO) 50 mM for 1 h. (2E)-3-[5-(2,3-dimethoxy-6-methyl
1,4-benzoquinoyl)] -2-nonyl-2-propenoic acid (E3330; custom
synthesized) [16] was solubilized in DMSO. Treatment with
E3330 was performed in serum-free William’s medium E in order
to prevent the serum albumin levels to affect E3330 final
concentration.
Treatment with recombinant human TNF-a (Peprotech Inc.,
Rocky Hill, NJ) was performed at 2000 U/ml in serum-free
William’s medium E to minimize serum-induced IL-8 release.
To induce fat-overloading of cells, JHH6 or HepG2 cell clones
were seeded at a density of 14000 and 57000 cells/cm2
respectively and after 24 h cells were exposed to a mixture of
long-chain FAs (oleate and palmitate) at 2:1 ratio. Stock solutions
of 100 mM oleic acid (Sigma-Aldrich) and 100 mM palmitic acid
(Sigma-Aldrich), prepared in DMSO, were conveniently diluted in
William’s medium E or DMEM high glucose containing 60 mM
albumin from bovine serum (Sigma-Aldrich) to obtain the desired
final concentrations. With mixtures of FAs and albumin, the
uptake is a function of free fatty acid (FAs), which is the
monomeric form in equilibrium with albumin-bound FAs [27].
Generation of APE1 overexpressing hepatic cell lines
For generation of APE1 overexpressing cell lines, an APE1
expression vector was generated by cloning an EcoRI-BamHI
fragment from pFLAG-CMV-5.1/APE1 (Sigma, Milan, IT) into
p3XFLAG-CMV-14 vector (Sigma). The APE1ND33 deletion
mutant was generated by PCR and subcloning from the full-
length cDNA sequence. Correctness of the cloning procedure was
confirmed by DNA sequencing. Then, HepG2 cells were
transfected with p3XFLAG-CMV/APE1, the wild-type APE1
(APE1WT) and the deletion mutant (APE1ND33), previously
digested with ScaI (Fermentas, St. Leon Rot, UK); 48 h after
transfection, the cells were subjected to selection with G418
(Invitrogen, Milan, Italy) for 14 days and selected for the acquired
resistance. Individual clones were isolated by using cell cloning
cylinders (Sigma), transferred and grown stepwise into 24-well, 12-
well, and 6-well plates for expansion to 107 cells in the presence of
selective antibiotic. As a control, we used cell clones transfected
with the p3XFLAG-CMV-14 empty vector. Geneticin (G418)
(PAA Laboratories GmbH, Pasching, AT) was added to the cell
culture medium at the final concentration of 300 mg/ml during
cell growth. Total cellular extracts were analysed for APE1
expression by immunoblotting, thus revealing the expression of the
ectopic flagged WT and the mutant form of the protein.
MTT and cell growth assays
To determine the viability of HepG2 cells over-expressing APE1
protein, a 3(4,5-dimethylthiazolyl-2)-2,5 diphenyl tetrazolium
(MTT) assay was performed [28]. HepG2 control and over-
expressing APE1 clones were seeded onto 96 multi-well plates at a
density of 70000 cells/cm2 for each well. The day after, cells were
incubated with MMS or H2O2 as indicated. After treatments, in
each well 1/10 volume of MTT solution (4 mg/ml in PBS) was
added and incubated for 2 h at 37uC. Then, the supernatant was
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removed and an equal volume of DMSO was added to the cells
and the MTT formazan was dissolved by pipetting. The
absorbance was measured on an ELISA plate reader (EL808
Ultra Microplate Reader Bio-tek Instruments, Winooski, VT) with
a test and reference wavelength of 570 and 630 nm, respectively.
For trypan blue exclusion experiments, cells were trypsinized,
resuspended in 0.08% w/v trypan blue (Sigma) in complete
medium, and counted after 3–5 min of incubation.
Data were expressed as percentage of surviving cells compared
with the untreated control.
MTS assay
The day before treatment, JHH6 cells were seeded at a density
of 26000 cells/cm2. To evaluate the effect of treatment in terms of
cell viability, the CellTiter 96H AQueous One Solution Cell
Proliferation Assay (Promega Corporation, Madison, WI) was
used according to the manufacturer’s instructions. This assay
contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS] that is bioreduced by cells into a colored
formazan product that is soluble in cell culture medium and can be
quantified by reading the absorbance at 490 nm.
Nile Red staining
The lipid content in cultured cells was determined fluorome-
trically by using Nile Red staining (Sigma-Aldrich, Milan, IT), a
vital lipophilic and selective fluorescent stain for intracellular lipid
droplets accumulation [29].
Stock solutions of Nile Red (100 or 1000 mg/ml) in acetone
were prepared and stored protected from light. Staining has been
carried out on fixed cells (1.5% glutaraldehyde, 5 min). Cell
monolayers were washed twice with PBS, treated for 5 min with
0,1% Triton X-100 in PBS and incubated for 1 h with Nile Red
solution to effect a 1:100 dilution in PBS. After Nile Red
treatment, nuclei were stained by 5 min incubation in 300 nM
solution of 49, 69-diamidino-2-phenylindole dihydrochloride
(DAPI) (Sigma) in PBS. Monolayers were then washed three
times in PBS and used for fluorescence microscopy. Immunoflu-
orescent images were collected using a confocal microscope (Leica
DM IRB/E, Wetzlar, Germany) at the excitation wavelength,
450–500 nm and emission wavelength .528 nm.
Preparation of total cell extracts
For preparation of total cell lysates, cells were harvested by
trypsinization and centrifuged at 2506g for 5 min at 4uC.
Supernatant was removed, and the pellet was washed once with
ice-cold phosphate-buffered saline (PBS) and then centrifuged
again as described before. Cell pellet was resuspended in lysis
buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, and 1% (wt/vol) Triton X-100 supplemented with
1x protease inhibitor cocktail (Sigma), 0.5 mM phenylmethylsul-
fonyl fluoride (PMSF), 1 mM NaF and 1 mM Na3VO4, at a cell
density of 107 cells/ml for 30 min at 4uC. After centrifugation at
12,0006g for 30 min at 4uC, the supernatant was collected as total
cell lysate. The protein concentration was determined using Bio-
Rad protein assay reagent (Bio-Rad, Hercules, CA).
Western blot analysis
The indicated amounts of cell extracts were electrophoresed
onto a 12% SDS-PAGE. Proteins were then transferred to
nitrocellulose membranes (Schleicher & Schuell, Keene, NH).
Membranes were saturated by incubation at 4uC overnight with
5% (wt/vol) nonfat dry milk in PBS–0.1% (wt/vol) Tween 20 and
then incubated with the polyclonal anti-APE1 antibody [17] for
3 h. After three washes with PBS–0.1% (wt/vol) Tween 20,
membranes were incubated with an anti-rabbit Ig coupled to
peroxidase (Sigma). Upon 60 min of incubation at room
temperature, the membranes were washed three times with
PBS–0.1% Tween 20 and the blots were then developed using
the ECL enhanced chemiluminescence procedure (PIERCE,
Rockford, IL). Normalization was performed with the polyclonal
anti-b-tubulin antibody (Sigma). Blots were quantified by using a
Chemi DOC XRS densitometer (Bio-Rad).
Immunofluorescence and confocal analysis
Twenty-four hours before the experiment, cells seeded at 46105
cells/cm2, were grown on glass cover slips. For APE1 immuno-
fluorescence experiments, HepG2 cell clones were fixed in 4%
(wt/vol) paraformaldehyde for 20 min at room temperature,
permeabilized for 5 min with PBS-0.25% (wt/vol) Triton X-100
and then incubated for 30 min with 10% (v/v) fetal bovine serum
(FBS) in PBS (blocking solution) to block unspecific binding of the
antibodies. Cells were then incubated overnight at 4uC with the
anti-FLAGH M2 Monoclonal Antibody-FITC Conjugate (Sigma)
diluted 1:100 in blocking solution. After washing, a second
blocking step for 30 min in the dark was performed, and then the
cells were incubated for 3 h with the second primary antibody,
rabbit-polyclonal to Histone H3 (Acetyl K18) (Abcam, Cam-
bridge, UK) in blocking solution. After washing, cells were
incubated for 90 min with secondary antibody Alexa Fluor 546-
conjugated goat anti-rabbit (1:500; Molecular Probes, Monza, IT).
The preparations were then washed with PBS three times for
5 min each in the dark. Nuclei were counterstained by 5 min of
incubation in 300 nM solution of 49, 69-diamidino-2-phenylindole
dihydrochloride (DAPI) (Sigma) in PBS. The preparations were
then washed three times in PBS for 5 min. The microscope slides
were then mounted onto slides with an anti-fade reagent.
Coverslips were visualized through a Leica TCS SP laser-scanning
confocal microscope (Leica Microsystems, Wetzlar, Germany)
equipped with a 488-nm argon laser, a 543-nm HeNe laser, and a
63x oil fluorescence objective.
For c-H2A.X immunofluorescence experiments, control and
etoposide-treated cells were washed with PBS, fixed for 20 min
with 4% (wt/vol) paraformaldehyde in PBS, and permeabilized for
5 min with 0.25% (wt/vol) Triton X-100 in PBS. Slides were
blocked with 10% (v/v) FBS in PBS, at 4uC, overnight, incubated
for 2 h at room temperature with anti-c-H2A.X antibody
(Stressgen, Ann Harbor, MI) and washed with 0.1% (wt/vol)
Triton X-100 in PBS. Anti-c-H2A.X antibody were used at
1:500 dilution. For detection, cells were incubated with Alexa
Fluor-488-labelled anti-mouse secondary antibody (Invitrogen,
Monza, IT). Nuclei were counterstained incubating cells with
0.3 mg/ml propidium iodide (PI) for 5 min, at 37uC. Cells were
washed and mounted in MowiolH 4–88 (Sigma) supplemented with
1:5 DABCO (Sigma) as anti-fade reagent. Images were collected
using a confocal microscope.
Quantification of c-H2A.X foci was carried out by BD Pathway
855, using 20X objective. Automated image analysis was
performed with customizable and highly flexible software tools.
Nuclear boundaries were generated using the Hoechst images.
The c-H2A.X images were acquired and data intensity was
analyzed using BD PathwayTM system software within the nuclear
boundaries.
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Transient transfection experiments
The constructs of human IL-8 promoter, 21498/+44 hIL-8/
Luc and 2162/+44 hIL-8 DNF-kB/Luc, were kindly provided by
Dr. S.E. Crowe [30].
One day before transfection, JHH6 cells were seeded in
triplicate in 96-well plates at a density of 31000 cells/cm2. Then
cells were transiently transfected with 200 ng of total DNA (hIL-8/
Luc promoter and pRL-CMV Renilla luciferase constructs in a
ratio of 49:1) per well, using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. The transfection reagent was removed 4 h post-
transfection and cells were incubated with complete medium for
16 h. The following day, cells were washed twice with PBS, pre-
treated with E3330 in serum-free William’s medium E and then
treated with TNF-a as reported in the text. Finally cells were lysed
with Dual-GloHLuciferase Assay System (Promega) according to
the manufacturer’s instructions. The luminescence signals were
quantified using a ModulusTM II Microplate Multimode Reader
(Turner Biosystems Inc., Sunnyvale, CA). Firefly luciferase activity
was normalized to the Renilla luciferase activity.
Real time PCR
Total RNA from cells was extracted using SV Total RNA
Isolation System (Promega) according to the manufacturer’s
instructions. Single-stranded cDNA was obtained using the
iScriptTM cDNA Synthesis kit (Bio-Rad Laboratories, Hercules,
CA) according to the manufacturer’s instructions.
Real Time quantitative PCR was performed with an CFX96TM
Real-Time PCR Detection Systems (Bio-Rad Laboratories);
Primers used were: IL-8 For 59-CTGGCCGTGGCTCTCTTG-
39, IL-8 Rev 59-CCTTGGCAAAACTGCACCTT-39; 18S For
59-CTGCCCTATCAACTTTCGATGGTAG-39, 18S Rev 59-
CCGTTTCTCAGGCTCCCTCTC-39; GAPDH For 59-
CCCTTCATTGACCTCAACTACATG-39, GAPDH Rev 59-
TGGGATTTCCATTGATGACAAGC-39; HPRT For 59-
AGACTTTGCTTTCCTTGGTCAGG-39, HPRT Rev 59-
GTCTGGCTTATATCCAACACTTCG-39.
cDNA was amplified in 96-well plates using primers for IL-8,
18S, GAPDH and HPRT in separate wells using the 2X iQTM
SYBRH Green Supermix (Bio-Rad Laboratories) [100 mM KCl;
40 mM Tris–HCl, pH 8.4; 0.4 mM of each dNTP; 50 U/ml iTaq
DNA polymerase; 6 mM MgCl2, SYBR Green I, 20 nM
fluorescein, and stabilizers] and 300 nM specific sense and anti-
sense primers in a final volume of 15 ml for each well. Each sample
was analysed in triplicate. A sample without template, as negative
control, and a sample with not retro-transcribed mRNA instead of
template cDNA, as control for genomic DNA contamination, were
included. The cycling parameters were: denaturation at 95uC for
10 s and annealing/extension at 60uC for 30 s (repeated 40 times).
In order to verify the specificity of the amplification, a melt-curve
analysis was performed, immediately after the amplification
protocol.
Soluble cytokines determination
IL-8 and IL-12 protein levels in TNF-a-treated cell-culture
supernatants were quantified using a FlowCytomix assay kit
(Bender MedSystems, Atlanta, GA), according to the manufac-
turer’s protocol.
Statistical analysis
Statistical analysis on biological data was performed using the
Microsoft Excel data analysis program for Student’s t-test analysis.
P,0.05 or P,0.01 were considered as statistically significant.
Results
Expression of ectopic APE1WT protein confers hepatic
cells protection toward genotoxic damage
We first investigated the biological effects of APE1 over-
expression on hepatic cells by using HepG2 cells, stably over-
expressing the ectopic form of the wild type protein (APE1WT) or
its deletion mutant (APE1ND33) lacking the first 33 residues [31].
The cell clones, in which the endogenous APE1 protein is co-
expressed with an ectopic Flag-tagged recombinant APE1 protein,
represent an overexpression model to test the role of functional
and non-functional APE1 proteins in lipid-induced cytotoxic effect
and mimics the condition found in advanced stages of liver cancer
progression (Fig. 1A) [14]. We characterized both cell models for
APE1 localization by immunofluorescence analysis, demonstrating
that, similarly to the endogenous protein, the ectopic APE1WT
localized mainly within the nuclear compartment of HepG2 cell
clones, while the APE1ND33 mutant showed a pan-cellular
distribution in both cytoplasmic and nuclear compartments, as a
consequence of the lack of the bi-partite NLS sequence [32] and as
already observed in other cell systems (Fig. 1B) [33].
Then, we evaluated the effect of the over-expression of APE1WT
and APE1ND33 functional mutant on cell viability. Over-expression
of APE1WT caused an increased cell proliferation rate, while
expression of the APE1ND33 protein form exhibited an apparent
impairment of cell growth as compared to the control cell clone
(Fig. 1C). Control cells showed an intermediate phenotype due to
the expression of only the endogenous APE1 protein. Cell viability
assays, evaluated through MTT analysis, showed that the
impaired proliferation observed in the APE1ND33 mutant was
associated to a reduced cell viability with respect to the APE1WT
expressing clone (Fig. 1D). These data support the conclusion that
the ND33 deletion mutant may act as a dominant negative form of
APE1 directly impacting on cell viability, as also seen in other
cancer cell models [17,34].
We then tested the ability of APE1 overexpression to protect
cells from genotoxic treatments, as described for other cell models
[35,36,37] but never in hepatic cells. To this aim, APE1WT and
APE1ND33 cell clones were treated with the DNA alkylating agent
methyl methanesulfonate (MMS) [38], with hydrogen peroxide
(H2O2) or with etoposide, which induces double strand breaks
(DSBs) in DNA. Cell clones were incubated with increasing doses
of MMS for 2 h, and cell viability was measured by MTT assay.
Upon treatment with 2.0 mM MMS, cell viability was significantly
reduced in the APE1ND33 expressing clone as compared with
APE1WT and control clones (Fig. 1E). Similar results were
obtained in the case of H2O2 as genotoxicant (Fig. 1F). These
results suggest that stably over-expressed APE1WT protects cells
against genotoxicity induced by alkylating treatment and oxidative
stress, as already observed in other cell lines [36].
In the case of DNA double-strand break analysis, cells were
treated for 1 h with 50 mM etoposide, an inhibitor of topoisom-
erase II that causes cytotoxic DSBs formation [39]. As the
phosphorylation occurring on S139 of H2A.X, called cH2A.X, is
important during DNA double-strand repair and is considered a
marker of DSBs cell damage [40], we analysed the kinetics of
etoposide-induced DSB repair by the different cell clones. After
1 h of etoposide treatment, cells were collected and the level of
cH2A.X was measured at 0 h, 15 h and 24 h to evaluate the
kinetics of repair associated with the expression of functional or
non-functional APE1 protein (Fig. 1G and Fig. S1). As observed in
Fig. 1G, the recovery from DSBs damage was strikingly different
in the three cell clones tested. In the case of the APE1ND33 cell
clone, the number of DSB-related cH2A.X foci remained
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Figure 1. Expression of ectopic APE1WT protein confers cells protection to genotoxic damage but not to FAs-induced cytotoxicity.
Panel A: Western Blot analysis of total cell extracts from HepG2 stable cell clones. Stably transfected clones have been obtained as described in
Materials and Methods section. Twelve micrograms of protein extracts were separated by 12% SDS-PAGE and then transferred onto a NC membrane.
The membrane was immunoblotted with anti-APE1 antibody. The values reported above refer to the ratios of the band intensities between
ectopically-expressed and endogenous APE1, as measured by densitometry. The ectopic Flag-tagged recombinant protein both in the APE1WT and
the APE1ND33 cell clones is expressed to a similar extent at different days of cell culture. a: clones after the sixth in vitro passage; b: clones after the
tenth in vitro passage. Panel B: APE1 localization within HepG2 cell clones. HepG2 cell clones were fixed and immunostained for Histone H3 (red)
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significantly higher than controls at both release times while the
amount of DSBs formation was lower in APE1WT expressing
clone. The repair kinetics was faster for the APE1WT than control
and the APE1ND33 expressing cell clones. As in the case of MMS,
the expression of the ND33 APE1 confers a deficient phenotype to
HepG2 expressing cells confirming the dominant-negative effect of
this mutant toward DNA breaking lesions.
FAs accumulation on HepG2 cells does not affect APE1
expression levels
To evaluate the effect of APE1 on lipotoxicity induced by FAs
accumulation, HepG2 cells were incubated with 600 mM of the
long-chain FAs mixture (oleate/palmitate) at the final ratio of 2:1
for 24 h. Fat-overloading and the extent of lipid uptake, were
assessed by transmission electron microscopy or by the fluorescent
lipophilic dye, Nile Red, a vital staining compound used for the
detection of intracellular lipid droplets by fluorescence microscopy
[29] (Fig. 2A,B). As determined by Western blot analysis, the FAs
treatment does not significantly alter the expression level of
endogenous APE1 protein both in APE1WT and APE1ND33 cell
clones (Fig. 2C). Lipotoxicity also did not differ between all cell
lines (Fig. 2D). These data demonstrate that, as opposed to what
was observed using genotoxic treatments, overexpression of
functionally active APE1 protein does not protect hepatic cells
from FAs-induced cytotoxicity.
NF-kB transcription factor regulates IL-8 promoter
activity in JHH6 cells and E3330 treatment inhibits TNF-a-
induced IL-8 promoter activity
IL-8 gene expression is mainly modulated at the transcriptional
level in a stimulus- and cell type-specific manner [41]. High levels
of IL-8 mRNA and APE1 protein expression may play an
important role in inflammatory liver injury as a consequence of
lipid accumulation. To determine the proper experimental model
in which testing the causal link between APE1 and IL-8
expression, we initially determined the expression levels of these
two genes in Huh-7, HepG2 and JHH6cell lines . As shown in
figure 3A, protein expression was highest in JHH6 cells, which
express approximately 2.5-fold higher levels of APE1 protein than
control Huh-7 cells. Then, we compared the expression levels of
IL8 gene in HepG2 and JHH6 cells through RT-PCR (Fig. 3B)
and observed that JHH6 cells express higher levels of IL8 than
HepG2 cells. These observations indicate that, with respect to
APE1 expression levels, JHH6 cells are a good model to investigate
the role of APE1 in the inflammatory process associated to liver
tumorigenesis.
IL-8 transcriptional responses to pro-inflammatory mediators
are rapid and require only 100 nucleotides of 59-flanking DNA
upstream of TATA-box. Within the IL-8 promoter sequence,
DNA binding sites for inducible transcription factors AP-1, NF-IL-
6 and NF-kB are present [30,42]. To investigate the role of NF-kB
on basal and TNF-a-induced IL-8 expression in JHH6 cells, we
evaluated the effect of deletion of the NF-kB binding site on IL-8
promoter sequence. We used a reporter assay approach to study
the effect of TNF-a on the IL-8 expression levels. Cells were
transiently transfected with luciferase-linked constructs of the wild-
type human IL-8 promoter 21498/+44 hIL-8/Luc and the
2162/+44 hIL-8/Luc DNF-kB in which the NF-kB binding sites
were deleted [30] (Fig. 3C). After transfection cells were stimulated
with TNF-a for 3 h to trigger NF-kB functional activation. As
shown in Fig 3D, TNF-a treatment significantly stimulated the IL-
8-promoter activity only in cells transfected with the 21498/+44
hIL-8/Luc plasmid while TNF-a stimulatory effect was completely
lost in cells transfected with deletion mutant promoter. Notably,
the basal transcriptional activity of the IL-8 promoter was
dependent on the presence of functional NF-kB binding sites
suggesting that the transcription factor NF-kB plays a central role
in both basal and TNF-a-induced IL-8 promoter activity.
Given that APE1 regulates NF-kB DNA binding activity in a
redox-dependent manner [11], we speculated if the specific
inhibitor of APE1 redox function, E3330 [16], was able to reduce
TNF-a-induced IL-8 gene expression. Accordingly, we evaluated
the effect of E3330 on cell viability. Analysis using the MTS assay
on JHH6 cells treated for 7 h with several doses (25–200 mM) of
E3330 revealed that E3330 has no cytotoxic effect up to a
concentration of 100 mM (Fig. 3E). We determined whether
E3330 treatment impairs subcellular APE1 trafficking in hepatic
cells, as previously observed in glioblastoma cells [17]. Immuno-
fluorescence experiments (Fig. 3F) clearly demonstrated that a
significant relocalization of APE1 protein from the nuclear to the
cytoplasmic compartment occurred in JHH6 cells with no
significant alterations in total protein levels, as measured by
Western blot analysis (data not shown). We then examined the
effect of E3330 on TNF-a-induced IL-8 promoter activation.
JHH6 cells were pre-treated with increasing concentrations of
E3330, for 4 h prior to treatment with TNF-a for 3 h. As shown in
figure 3G, pre-treatment with E3330 significantly attenuated
TNF-a-induced IL-8 promoter activity in a dose-dependent
manner.
and for Flag-tagged APE1 with an a-Flag antibody (green). Merged images (yellow) show the localization of APE1WT within cell nuclei and
colocalization with Histone H3. The APE1ND33 deletion mutant colocalizes with Histone H3 within cell nuclei but show also cytoplasmic positivity.
Panel C: Growth curve of HepG2 cell clones. HepG2 empty clone, APE1WT clone and APE1ND33 clone cells were seeded into each well of a 24-well
plate and cell growth was monitored every two or three days as indicated, by trypan blue exclusion. APE1ND33 cells (triangle) grew more slowly than
the APE1WT (square) and the empty clones (dot). Panel D: Cell growth by MTT colorimetric assay. Thirty thousand cells of the control (empty clone),
APE1WT and APE1ND33 clones were seeded in quadruplicate wells in a 96-well microculture plate. Cell viability was measured after 72 h of culture. MTT
assay also revealed that APE1ND33 cell clone has a lower level of proliferation than empty and APE1WT clones. Data, expressed as the percentage of
cell viability with respect to the control empty clone, are the means 6 SD of three independent experiments. Panel E: Effect of MMS on viability of
HepG2 cell clones. HepG2 cell clones were treated for 2 h with 1.6 or 2.0 mM MMS and cell viability was estimated by the MTT colorimetric assay.
When cells were treated with 2.0 mM MMS, cell viability was significantly decreased in the APE1ND33 cell clone but not in the APE1WT clone,
suggesting that the ectopic expression of APE1WT protects cells against MMS-induced citotoxicity. Data shown are the means 6 SD of three
independent experiments. Panel F: Effect of H2O2 on viability of HepG2 cell clones. HepG2 cell clones were treated with 2.5 mM hydrogen
peroxide for 1 h, then cell viability was determined by the MTT assay. After exposure to 2.5 mM H2O2 no significant decrease in cell viability was
detected for APE1WT clone compared to empty and APE1ND33 cell clones. The histograms show the means 6 SD of three independent experiments.
Panel G: Quantification of cH2A.X foci in response to etoposide treatment. The cH2A.X foci were detected using immunohistochemistry and
quantified by image analysis. Cells were treated with etoposide (50 mM) for 1 h and the number of double strand DNA breaks (DSBs) was determined
at different times of release (0 h, 15 h and 24 h). cH2A.X foci levels remain significantly higher than controls at 15 h and 24 h in etoposide treated
APE1ND33 cell clone (triangle). DNA damage was weaker for APE1WT clone (square) than empty (dot) and APE1ND33 cell clones, suggesting a protective
role of APE1 overexpression in DNA repair.
doi:10.1371/journal.pone.0070909.g001
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Figure 2. Overexpression of APE1 protein does not protect HepG2 cells from FAs treatment. Panel A: Nile Red staining. Fluorescence of
Nile Red-stained were measured on HepG2 cells previously incubated with 600 mM FAs mixture (oleate/palmitate 2:1) for 24 h (b and d) or left
untreated as control (a and c). Cells were fixed with 1.5% glutaraldehyde in PBS, washed with buffered saline and then were stained with Nile Red
10 mg/ml (a and b) or 100 mg/ml (c and d). As confirmed by Nile Red staining, HepG2 cell line exhibited a fat overloading profile. Panel B:
Transmission electron microscopy analysis. HepG2 cells were treated with the 600 mM FAs mixture at the final ratio of 2:1 (oleate/palmitate) for 24 h
(b and d) or left untreated (a and c). Cells were then fixed and paraffin-embedded. Transmission electron microscopy confirmed fat overloading
induction in HepG2 cell line. Magnification: 6300X (a and b) and 8000X (c and d). Panel C: Western Blotting analysis of total cell extracts from
HepG2 stable cell clones after FAs treatment. HepG2 cell clones were treated with 600 mM of FAs mixture (2:1 ratio of oleate/palmitate) for 24 h or
left untreated as control. After FAs treatment, total cell extracts were prepared and 12 mg of protein extract was loaded onto a 12% SDS-PAGE,
blotted and probed with anti-APE1 antibody. FAs treatment does not alter the endogenous levels of APE1 both in the APE1WT and the APE1ND33 cell
clones. Panel D: Effect of FAs treatment on viability of HepG2 cell clones. HepG2 cell clones were treated with 600 mM of FAs mixture (2:1 ratio of
oleate/palmitate) for 24 h. Cytotoxicity was assessed by trypan blue exclusion test. After exposure to FAs there was a significant reduction in cell
viability but no significant difference between the clones. Data, expressed as the percentage of cell viability, are the means 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0070909.g002
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Figure 3. NF-kB transcription factor regulates IL-8 promoter activity in JHH6 cells and E3330 treatment inhibits TNF-a-induced
promoter activation. Panel A:Western Blotting analysis of total cell extracts from human hepatocellular carcinoma cell lines. A representative
Western blot analysis for the evaluation of APE1 expression in Huh-7, HepG2 and JHH6 cell lines is shown in the upper panel. b-Tubulin was always
measured as loading control and was used for data normalization. The lower panel shows expression levels of the protein obtained after
densitometric analysis of the bands. An almost two-fold increase was observed in the content of APE1/Ref-1 in JHH6 cell line compared to Huh-7.
Values were reported as histograms of the ratio between APE/Ref-1 band intensities and b-Tubulin. Data are the means 6 SD of three independent
experiments. Panel B: IL-8 mRNA expression in human hepatocellular carcinoma cell lines. IL-8 mRNA levels were evaluated on HepG2 and JHH6
cell lines by Real-Time PCR. Total RNA was extracted and reverse-transcribed as described in Material and Methods section. The histograms show the
detected levels of IL-8 mRNA normalized to two different housekeeping genes (18S and GAPDH). An almost thirty-fold increase was observed for the
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E3330 treatment specifically decreases both TNF-a- and
FAs-induced IL-8 endogenous gene expression
To investigate the effect of E3330 on TNF-a-induced IL-8
expression, JHH6 cells were pre-treated with 100 mM E3330 for
4 h before exposure to TNF-a. As shown in figure 4, pre-
treatment with E3330 significantly decreased TNF-a-induced IL-8
expression in terms of both endogenous mRNA transcription
(Fig. 4A) and protein production (Fig. 4B). We confirmed the
inhibitory effect of E3330 on IL-6 expression (Fig. 4C), another
cytokine activated by NF-kB which is induced by FAs accumu-
lation. Interestingly, E3330 does not affect TNF-a-induced IL-12
protein secretion suggesting a specific effect of E3330 on IL-8 and
IL-6 gene expression, at least in our experimental system (Fig. 4D).
These data point to a potential use of E3330 to reduce the
inflammatory processes in liver diseases such as those associated
with NASH.
To investigate whether FAs overloading could play a role in the
development of inflammation through induction of IL-8 produc-
tion, we used the in vitro cell model of hepatic steatosis, i.e. JHH6
cells, described above. JHH6 cells were treated for different times
with 800 mM of mixture of oleate/palmitate (2:1 ratio). This
treatment had not effect on cell viability (data not shown) while IL-
8 mRNA expression was increased in a time-dependent manner
(Fig. 4E). To investigate the effect of E3330 on FAs-induced IL-8
expression, JHH6 cells were pre-treated with 100 mM E3330, for
4 h prior to treatment with 800 mM FAs for 3 h. As shown in
Figure 4F, pre-treatment with E3330 significantly decreased FAs-
induced IL-8 expression.
Discussion
The current work was aimed at elucidating the role and the
impact of APE1 in the onset of inflammatory circuits in liver
diseases, such as those associated to NASH and to evaluate
whether the APE1 redox inhibitor, i.e. E3330, may prevent the
induction of IL-8 and IL-6 expression by both TNF-a or FA
treatment.
Our data demonstrate that in hepatic cancer cell lines APE1
redox function is involved in TNF-a and FA-induced IL-8- and
IL-6 expression, and its inhibition by E3330 may represent a
promising tool for reducing the early inflammatory process in liver
diseases such as in NASH. NASH is a clinically relevant pathology
since the high prevalence in the general population and the
possible evolution towards pathologies with a fatal outcome [2].
NASH has been correlated with direct lipid toxicity, impaired
mitochondrial function, elevated cytochrome P450 activity (spe-
cifically CYP2E1 and CYP4A10/4A14), oxidative damage and
increased inflammatory cytokines levels in the liver and periphery
[9]. Since a better understanding of the molecular events
regulating these mechanisms may be helpful in designing new
therapeutic strategies, we utilized an in vitro hepatic model to study
the pathway responsible for inflammatory cytokines production
(IL-8 and IL-6) triggered by FAs accumulation and TNF-a
stimulation (Fig. 5). In this pathway, mitochondrial impairment
and resulting oxidative stress condition may cause the functional
activation of NF-kB transcription factors through APE1 regulatory
redox function leading to IL-8 and IL-6 gene expression.
To create a lipotoxic condition and a pro-inflammatory status,
we treated JHH6 cells with FAs or TNF-a. In fact, it has been
demonstrated in different models that FAs increase the expression
of inflammatory cytokine through mechanism involving activation
of NF-kB [7,8,9]. Also, TNF-a plays an important role in
inflammatory liver injury. Accordingly, intrahepatic gene expres-
sion and/or plasma levels of TNF-a are increased in fatty liver and
in NASH patients [43] and modulation of TNF-a expression by
genetic deletion or other means results in the amelioration of
steatosis, inflammation, and hepatocyte damage in ob/ob mice and
in dietary models of steatohepatitis [44] suggesting a pivotal role of
this cytokine in NASH. Moreover, interference with NF-kB
activation significantly protected from the development of
steatohepatitis, and reduced the expression of TNF-a and
ICAM-1 [45]. These observations suggest that TNF-a is one of
the multiple effectors of steatohepatitis, and that NF-kB activation
plays a pivotal role in the early onset and maintenance of the
inflammatory process.
In the molecular pathway represented in Figure 5, the cellular
damage due to FAs or TNF-a treatment is principally mediated by
mitochondrial impairment. In fact the impairment in free FAs b-
oxidation is at the basis of the onset of NASH. Mitochondria are
involved in both free FA b-oxidation and reactive oxygen species
(ROS) generation. Patients with NASH are characterized by
abnormal mitochondria from both a functional and a morpho-
logical point of view. Accumulating evidence indicates that
respiratory chain defects are key-determinant of mitochondrial
dysfunction and thus oxidative stress generation [9]. Chemical
modification of essential biomolecules by ROS and RNS cause
their functional inactivation and lead to either cell death or to an
adaptive cellular response, e.g. activation of redox-sensitive
transcription factors [46] (nuclear factor NF-kB, Nrf-1 and Sp-1)
contributing to the production of pro-inflammatory and fibrogenic
mediators by Kupffer cells and HSC. Of interest is the recent
finding of a role for the transcription factor Nrf-1, a central player
mRNA IL-8 expression in JHH6 cell line. Data are the means 6 SD of three independent experiments. Panel C: Schematic representation of the
luciferase-linked human IL-8 promoter constructs used in this study. The plasmids 21498/+44 hIL-8/Luc and 2162/+44 hIL-8/Luc (deleted of a 59
promoter region) contain binding sites for AP-1, NF-IL-6 and NF-kB transcription factors. Site-directed mutation of the IL-8 NF-kB binding site in the
context of the 2162/+44 hIL-8/Luc plasmid abolished the binding of NF-kB on IL-8 promoter. Panel D: Effect of site-directed mutagenesis of the
NF-kB binding site in the human IL-8 promoter sequence. JHH6 cells transfected with 21498/+44 hIL-8/Luc or 2162/+44 hIL-8/Luc DNF-kB
constructs and then treated with 2000 U/ml of TNF-a for 3 h, were analyzed through gene reporter assay. In cells transfected with the 21498/+44
hIL-8/Luc construct, TNF-a stimulated IL-8 luciferase activity, whereas mutation of the NF-kB binding site significantly decreased both basal and TNF-
a-induced IL-8 promoter driven activity in JHH6. Data reported are the means 6 SD of three independent experiments. These data suggest a central
role of NF-kB in IL-8 gene transcription. Panel E: Effect of E3330 treatment on JHH6 viability. Levels of viability were measured with MTS assay in
JHH6 cells treated for 7 h with increasing doses of E3330. Up to a concentration of 100 mM the treatment with E3330 did not affect the cellular
viability. Data, expressed as the percentage of cell viability, are the means6 SD of three independent experiments. Panel F: Effect of E3330 on APE1
subcellular distribution. APE1 subcellular localization was detected through confocal microscopy analysis using a specific a-APE1 monoclonal
primary antibody. APE1 mainly localized within the nuclear compartment and accumulated into nucleoli. Treatment with 100 mM E3330 for 6 h
induced a robust cytoplasmic enrichment of APE1. As control, cells were treated with DMSO without any effect on APE1 subcellular distribution.
Panel G: Effect of E3330 treatment on TNF-a-induced IL-8 promoter activity. JHH6 cells transfected with21498/+44 hIL-8/Luc construct were pre-
treated with increasing concentration of E3330, or with vehicle (DMSO) as a control, for 4 h prior to treatment with 2000 U/ml TNF-a for 3 h. TNF-a
stimulated IL-8 luciferase activity and the pre-treatment with E3330 significantly decreased, in a dose-dependent manner, TNF-a-induced IL-8
promoter activity. Data reported are the means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0070909.g003
APE1 Redox Activity Regulates IL8 Expression
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e70909
Figure 4. E3330 treatment specifically inhibits TNF-a- and FAs-induced IL-8 endogenous gene expression. Panel A: Effect of E3330
treatment on TNF-a-induced IL-8 mRNA expression. JHH6 cells were pre-treated with 100 mM E3330 or with vehicle (DMSO) as a control, for 4 h
prior to treatment with 2000 U/ml TNF-a for 2 h. IL-8 mRNA expression was determined by Real-Time PCR. The histograms show the detected levels
of IL-8 mRNA normalized to control (DMSO) and normalized to two different housekeeping genes (GAPDH and HPRT). IL-8 mRNA expression was
increased by TNF-a treatment when compared with control cells and pre-treatment with 100 mM E3330 decreased TNF-a-induced IL-8 mRNA. Data
reported are the means 6 SD of three independent experiments. Panel B: Effect of E3330 treatment on TNF-a-induced IL-8 protein production.
JHH6 cells were pre-treated with 100 mM E3330 or with vehicle (DMSO) as control, for 4 h prior to treatment with 2000 U/ml TNF-a for 2 h. The
supernatants of the same cells analyzed for mRNA were assayed for IL-8 protein by FlowCytomix assay kit. TNF-a stimulated the secretion of IL-8
protein by JHH6 cells and the pre-treatment with 100 mM E3330 significantly suppressed TNF-a-induced IL-8 protein release. Data reported are the
means 6 SD of three independent experiments. Panel C: Effect of E3330 treatment on TNF-a-induced IL-6 mRNA expression in JHH6 cells. JHH6
cells were pre-treated with 100 mM E3330 or with vehicle (DMSO) as a control, for 4 h prior to treatment with 2000 U/ml TNF-a for 3 h. IL-6 mRNA
expression was determined by Real-Time PCR. The histograms show the detected levels of IL-6 mRNA normalized to control (DMSO) and normalized
to two different housekeeping genes (GAPDH and HPRT). IL-6 mRNA expression was increased by TNF-a treatment and the pre-treatment with
100 mM E3330 significantly decreased TNF-a-induced IL-6 mRNA. Data reported are the means 6 SD of three independent experiments. Panel D:
Effect of E3330 treatment on TNF-a-induced IL-12 protein production in JHH6 cells. The same supernatants analyzed for IL-8 protein were assayed
for IL-12 protein by FlowCytomix assay kit. E3330 does not affect TNF-a-induced IL-12 activation suggesting a specific effect of E3330 on IL-8 gene
expression. Data reported are the means 6 SD of three independent experiments. Panel E: Effect of FAs overload on IL-8 gene expression. JHH6
cells were treated for different times with 800 mM of mixture of oleate/palmitate (2:1 ratio) and IL-8 mRNA expression was determined by Real-Time
PCR. The histograms show the detected levels of IL-8 mRNA normalized to control (DMSO) and normalized to two different housekeeping genes
(GAPDH and HPRT). IL-8 mRNA expression was increased by FAs treatment when compared with control cells in a time-dependent manner. Data
reported are the means 6 SD of three independent experiments. Panel F: Effect of E3330 treatment on FAs-induced IL-8 mRNA expression. JHH6
cells were pre-treated with 100 mM E3330 or with vehicle (DMSO) as a control, for 4 h prior to treatment with 800 mM of mixture of oleate/palmitate
(2:1 ratio) for 3 h. IL-8 mRNA expression was determined by Real-Time PCR. The histograms show the detected levels of IL-8 mRNA normalized to
control (DMSO) and normalized to two different housekeeping genes (GAPDH and HPRT). IL-8 mRNA expression was increased by FAs treatment and
pre-treatment with 100 mM E3330 decreased FAs-induced IL-8 mRNA. Data reported are the means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0070909.g004
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in controlling expression of antioxidant genes through binding to
ARE sequences, in NASH and hepatic cancer development [47].
Interestingly, both Nrf-1 and APE1 are over-expressed in liver
cancer [14]. Very recently, Li et al demonstrated that APE1 acts as
a new redox coactivator of Nrf-1 regulating the expression of Tfam,
Cox6c, and Tomm22 nuclear genes with mitochondrial function.
This evidence highlights an additional regulatory role for APE1 in
the maintenance of mitochondrial functionality upon oxidative
stress and provides the first hypothesis for an indirect mitochon-
drial function of APE1 through a nuclear transcriptional
mechanism [48]. Collectively, these findings suggest that the
APE1-Nrf-1 axis deserves further attention.
For a better understanding of the role of APE1 in the onset of
inflammatory circuits in liver diseases, we wondered whether
APE1 overexpression would protect hepatic cells from the
cytotoxic effects of genotoxicants and from lipid induced
cytotoxicity. We used HCC-derived cell line overexpressing
functional and non-functional APE1 proteins. Due to the
prominent role played by APE1 in the repair of specific oxidative,
alkylation, and enzymatic DNA intermediates, we treated cells
with different DNA damaging agents, including MMS, hydrogen
peroxide and etoposide. The results show the expected protective
function of APE1 towards these genotoxic agents [36,49],
confirming the validity of the cell model developed. Moreover,
they suggest that the upregulation of APE1 protein expression
levels observed in hepatic cancer cells may reflect an adaptive
response to cell damage and may be responsible for further cell
resistance to chemotherapy, as shown in other cancer cell models
[49,50]. However, the same protection was not evident in the case
of FAs cytotoxicity. Data obtained also suggested that the increase
of APE1 protein observed both in NASH models and in liver tissue
obtained from NASH patients [13] may result as the consequence
of lipid-induced hepatocellular injury. The damage may be
explained on the basis of APE19s roles in intracellular signalling
as a transcriptional coactivator rather than its role as DNA repair
enzyme. The deficient phenotype, observed in the case of the
ND33 mutant expressing cells, confirms the dominant-negative
effect of this mutant toward DNA breaking lesions. This effect may
be due to the loss of BER coordination as the consequence of the
impairment of APE1 protein-protein interactions (which is in fact
modulated by the first 33–35 N-terminal amino acids of APE1)
Figure 5. Model of the effect of E3330 redox inhibitor on the Fatty Acid-TNFa-APE1-NFkB-IL8 axis. APE1 redox inhibitor E3330 prevents
inflammatory cytokines production (IL-8 and IL-6) triggered by FAs accumulation and TNF-a stimulation in hepatic cancer cell lines. In this pathway,
mitochondrial impairment and resulting oxidative stress condition may cause the functional activation of NF-kB transcription factor through APE1
regulatory redox function leading to IL-8 and IL-6 gene expression.
doi:10.1371/journal.pone.0070909.g005
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and to the concurrent competition of the ND33 mutant with the
WT form for the same damaged substrates [17,33].
Since APE1 is upregulated in hepatic cancer cells, the APE1
overexpression cell model used for this study can be compared to
the condition observed in advanced stages of liver cancer
progression [14]. The protective role of APE1 from genotoxicants
suggest that its up-regulation may occur as an adaptive response to
cell damage and may be associated with the onset of cancer
resistance. Since APE1 has emerged as an excellent target for
sensitizing tumor cells to chemotherapy [50,51,52,53], APE1
DNA-repair and redox-inhibition may be used as a promising
strategy for liver cancer treatment [34,54]. Recent studies have
demonstrated a direct effect of E3330 on a variety of cancer cells
[55,56] and that E3330 has potential efficacy in pancreatic cancer.
In fact, inhibition of APE1 via E3330 results in tumor growth
inhibition in cell lines and pancreatic cancer xenograft models in
mice. These effects of E3330 are accomplished through the redox
inhibition of APE1 on the activity of NF-kB, AP-1, and HIF1a
that are key transcriptional regulators involved in survival and
invasion, and may lead to the blockage of the metastatic process
[20]. E3330 directly interact with APE1 and inhibits its redox
activity by increasing the formation of disulfide bonds by Cys-65,
increased unfolding of the protein, and decreasing the protein
redox active population [15]. APE1 subcellular distribution within
different mammalian cell types is mainly nuclear and critically
controls cellular proliferative rate [37,57]. We recently demon-
strated, in the human glioblastoma cell line SF767, that E3330
treatment caused a significant relocalization of APE1 from the
nuclear to the cytoplasmic compartment with no significant
alterations in total protein levels. Moreover, kinetic experiments
also demonstrated that E3330 treatment caused a progressive
emptying of the nucleoli. These data demonstrate that some of
E3330 effects are associated with alterations of APE1 trafficking
and that the redox state of C65, or the altered configuration of the
APE1 protein, may control APE1 cellular distribution providing
the basis for a new role for this residue in controlling subcellular
distribution [17]. In this study, we demonstrated that in JHH6
hepatic cancer cells, E3330 treatment inhibits TNF-a-induced IL8
production through impairment of APE1 subcellular distribution,
thus confirming a novel aspect of E3330 effect on APE1
modulation. It would also be interesting to check whether the
redox state of APE1 may explain the cytoplasmic accumulation
already observed in HCC [14].
In comparison with other cell types as pancreatic cell lines [58]
we noticed that the hepatic cancer cell lines were less sensitive to
E3330 treatment in terms of cell viability. For example, in PDAC
pancreatic cancer cell line and primary patient cells, E3330 has
little killing or growth effect until concentrations greater than
67.5 mM are reached [20,59]. Other studies using E3330 at
concentrations similar to or above 100 mM have been published
including cellular EMSA assays [60], a reduction of APE1 nuclear
location after 140 mM E3330 treatment without cell killing [17],
and cell survival in human hepatocellular cell lines [61] after
100 mM treatments. Recent data obtained in LPS-activated
macrophages, demonstrated that E3330 suppresses the inflamma-
tory response. Via the inhibition of APE1 redox function on NF-kB
and AP-1 transcriptional activity, E3330 suppresses secretion of
inflammatory cytokines including TNF-a, IL-6 and inflammatory
mediators such as nitric oxide and prostaglandin E(2) [21]. These
results and data presented here are in agreement with other
reports demonstrating the hepatoprotective effect of E3330 against
endotoxin-mediated hepatitis and alcoholic liver injury. In fact in
endotoxin-induced murine hepatitis models, E3330 attenuates the
elevation of plasma TNF activity suggesting that E3330 protects
mice from liver injury through the inhibition of TNF production
[62]. In an experimental alcoholic liver injury rat model, E3330
reduces thromboxane B2 and leukotriene B4 levels in both
nonparenchymal cell supernatant and plasma and reduces TNF
levels in nonparenchymal cell supernatant. These findings suggest
that E3330 has a protective effect in alcoholic liver injury trough
inhibition of thromboxane, leukotriene and TNF generation [63].
All these observations underscore the relevance of using E3330 for
treatment of inflammatory-based liver diseases and the need of
further in vivo studies in NASH animal models.
Supporting Information
Figure S1 Immunofluorescence staining for double
strand DNA damage. HepG2 cell clones were incubated with
or without etoposide (50 mM) for 1 h. After the incubation and the
time course for the release, cells were fixed, permeabilized and
stained for the phosphorylated form of the histone H2A.X using a
specific antibody (green). Nuclei were detected with Propidium
Iodide (red). Scale bar correspond to 20 mm.
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